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Cyclic Arg-Cly-Asp-Phe-Val peptides with either D-Pile or D-Val residues were 20- to more than IOO-fold better inhibitors of ccl1 adhesion to 
vitronectin and/or laminin fragment Pl when compared to a linear variant or Gly-Arg-Gly-Asp-Ser. No or only little increase in inhibitory capacity 
was observed for fibronectin adhesion and for the binding of platelet receptor aIIbj33 to fibrinogen. NMR studies of the two most active cyclic 
peptides showed for both an all-tram conformation with a PII’ and y turn. Subtle conformational differences, however, exist between both peptides 
and may contribute to selectivity of inhibition. 
Conformation; Fibrinogen receptor; Integrin; NMR: Synthetic peptide 
1. INTRODUCTION 
The identification of the Arg-Gly-Asp (RGD) se- 
quence as a cell adhesion site in fibronectin [1,2] was a 
major breakthrough in the molecular characterizatiou 
of cell-matrix interactions. It was subsequently shown 
that several more proteins including vitronectin, von 
Willebrand factor, fibrinogen, thrombospondin and la- 
minin are RGD-dependent adhesion proteins which 
bind to a variety of either specific or promiscuous inte- 
grin receptors [3-61. Each residue in the tripeptide se- 
quence appears to be crucial since conservative rcplace- 
ments in most cases abolish activity of synthetic pep- 
tides [2,7]. Contributions by residues adjacent o RGD 
are also known [$I, Yet these data do not readily explain 
the selectivity of RGD recognition by distinct integrins 
nor the possibility that RGD in a number of proteins 
may be non-functional. The variation of cell adhesion- 
inhibiting activity by restricting the conformational 
space of active peptide sequences, by using them in 
cyclic form, could lead to components with improved 
activity and receptor selectivity [9], This seems feasible 
as shown for a cyclic synthetic RGD-peptide being a 
better inhibitor of vitronectin than fibronectin adhesion 
[8] and for several snake venom RGD-containing pep- 
tides named disintegrins [lo]. In both cases conform- 
ational constraints imposed by disulfide bridges [11 ,121 
were important for improving biological activity. In the 
present approach we used RGD pentapeptides in which 
a single D-amino acid induces defined conformational 
motifs and facilitates cyclization ot requiring disulfide 
bonds. Two variants showed 20- to lOO-fold higher in- 
hibiting activity than linear GRGDS for cell adhesion 
to some but not all protein substrates tested. Based on 
2D NMR spectroscopy and molecular dynamics (MD) 
simulations in solution, we also propose a distinct rela- 
tionship between activity and conformation. 
2. EXPERIMENTAL 
Laminin fragments Pi [I31 and ES [l4] were prepared from the 
laminin-nidogen complex obtained from the mouse Engelbrcth- 
Holm-Swarm tumor, Human plasma fibronectin (Behringwerke, AC?) 
and vitronectin [I 51 wcrc obtained by chromatography on hcparin- 
Sepharose, Fibrinogen from human plasma was a kind gift of Dr H. 
Hotmann, Martinsried. Integrin aIIbp3 (GPIIb/llIa) was purified 
from human platelets [l6] and biotinylated with NHS-LC-biotin fol- 
lowing the manufacturer’s (Pierce) instruction. Cyclic pcptidcs were 
synthesized by the solid phase method with Fmoc protected amino 
acids using dicyclohexylcarbodiimide/l-hydroxybcnzotri;lzolc as cou- 
pling rcagcnts. After relcasc from the resin by mild acid treatment. 
cyclization was achieved in high dilution with diphcnylphosphoryl 
azidc at pH 8.5. followed by removal of side chain protecting groups 
under strong acidic conditions, The pcptidcs wcrc then puritied by 
rcvcrscd phase HPLC and charactcrizcd by fast atomic botnh;trdmcnt 
tnass spectroscopy. Linear GRGDS was supplied by Dr W. Ktinig, 
Hocchst. AG. 
Ci~rrcs~)mtrilerr ecu dfrc~.w: I? , Timpl, Milx-Plalrck-fnstitut fur Ilioche- 
mic, 0.8033 Martinsricd. Gcrmi~ny. Fax: (49; $39) 8.578 2422. 
Conformation of cyclic pcptidcs was studied by NMR and MD 
simulations [17,18]. All NMR spectra wcrc acquired on Liruker AMX 
500 and AMX 600 spcctromctcrs and proccsscd on a Urukcr X32 
computer. The ‘H assignment and the sxtraction of confortnnliollally 
rclcvant parantctcrs (coupling constants, tcmpcralurc cocfficirnts, in- 
tcrproton distanros) vwc achicvcd by a set of 5UO MHz and 600 MHz 
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ID and 2D NMR spectra (TOCSY, ECOSY, NOESY). For structure 
refinement restrained MD simulations were performed in vacua and 
in solution over 150 ps. All calculations were performed on Silicon 
Graphics 4D/25GT, 4D/70GTB and 4W24OSX computers using the 
software package INSIGHT (BIOSYM) for graphical display and 
model building and the programs from the Groningen molecular simu- 
lation system (GROMO§) for all energy minimization and molecular 
dynamics simulations [19]. The NOES were included in the potential 
energy function with a harmonic potential. Parameters for MD 
simulations in DMSO are based on unpublished work [31]. 
Optimal substrate coating of microtiter wells and analysis of adhe- 
rent cells by a coloeimetric assay have been described [to]. The human 
cell lines usesd wcrc melanoma A375, mammary epithelia HBL-100 
and fibrosarcoma I-IT 1080 [21,22]. In the inhibition assay, a ccl1 
suspension (0.5-2 x 1 OS cells/ml) in Dulbccco’s modified Eagle’s me- 
dium was mixed with the peptide solution and immediately placed into 
the coated wells. Biotinylated integein aIIb/?3 was used in binding 
assays with immobilized ligands [23] using streptavidin-peroxidase 
conjugate and 5-amino-2-hydroxybenzoic acid for detection. In inhibi- 
tion a fixed concentration of biotinyl-aIIbp3 (100 nM) was preincuba- 
ted with increasing amounts of peptides (I h, 25OC), prior to adding 
the mixture to the fibrinogen coat for another hour. 
3. RESIJLTS AND DISCIJSSION 
Previous studies have shown that levels of inhibition 
of cell adhesion by a linear GRGDS peptide or other 
linear variants differ with the substrate used, being high 
(ICSO - lo-50 AIM) for vitronectin and laminin fragment 
Pl but low (ICsO - 100-1000 puM) for fibronectin 17,131. 
We have compared these substrates using cyclic 
RGDFV peptides and linear GRGDS as inhibitors. In- 
troduction of D-Phe into the cyclic structure 
(cRGD?V) increased inhibition of A375 cell adhesion 
to lammlm PI by ZO-fold and to vitronectin by IOO-fold 
compared to GRGDS (Pig. 1). The use of D-Val in the 
cyclic sequence was more selective as it showed a dis- 
tinct increase in inhibitory activity only for Iaminin PI 
substrate. These observations were confirmed with 2 
other cell lines and extended to more variants of the 
cyclic structure (Table I). Introduction of a single D- 
Table I 
Arg or D-Asp into the cyclic peptide produced a distinct 
drop in inhibiting activity below the level of linear 
GRGDS. The same was observed for replacing Gly in 
the cyclic peptides by either D-Ala or L-Ala, in the latter 
case the D-Phe being maintained. 
The increase in activity for some cyclic peptides is 
apparently due to cycliaation rather than introducing a 
D-amino acid as shown for linear RGDFY which in 
most cases was of distinctly less inhibitory activity com- 
pared to GRGDS (Table I). Variations in this ac;tivity 
have been previously recognized in some, but not all, 
linear RGD sequences being adjacent to a hydrophobic 
amino acid residue [g,24]. 
The adhesion of 2 cell lines (A375 HBL-100) to vitro- 
nectin very likely includes in part the classical vitronec- 
tin receptor 0~433 present on these cells to a variable 
extent [21]. Since we could only partially inhibit adhe- 
sion by either a P3-specific monoclonal antibody Cl7 
[25] or an antiserum against fibronectin receptor with 
a strong titer for the pl subunit, the more recently de- 
scribed vitronectin receptors [6] av@l and possibly avB5 
may also participale. Similar antibody inhibition pat- 
terns were also observed for adhesion to Iaminin Pl [21 J
while an inhibiting monoclonal antibody to the fibro- 
nectin receptor &5 subunit was inactive. This indicates 
,that high inhibiting activity of cyclic pentapeptides may 
involve several but not all RGD-dependent integrins. 
The 3 cell lines (Table I) also adhere strongly to fibro- 
nectin and 2 of them, I-IT1080 and I-IBL-100, to colla- 
gen type IV and laminin fragment ES. These interac- 
tions were used to compare GRGDS with the most 
active cRGDFV peptide. Both peptides were of similar 
inhibiting activity (I& - 270-500 @VI) for fibronectin 
adhesion demonstrating that the high activity of the 
cyclic D-Phe peptide (I& = 0.1-4yM) with vitronectin 
and laminin PI substrates is an effect which is specific 
for the receptor(s) recognizing these substrates. Cell ad- 
Inhibitory capacity (I&) of cycle (Arg-Gly-Asp-Phe-Val) derivates containing D-amino acids or Gly-to-Ala substitutions for ccl1 adhesion on 
vitrontctin (VN) or laminin fragment PI and for alIbp3 intcgrin binding to fibrinogen (Fb). Comparison was with linear GRGDS and RGDF_V_ 
pcptides 
Inhibitor ICso O1M) 
cRGDFV 
cRGDFV 
cRGDI-V 
cRAD,FV 
rRADFV 
cRGDFV 
GRGDS 
RGDFV 
A375 HBL-100 I-lT1080 alIbJ33 
PI VN PI VN Pi VN Fb 
1.0 0.2 0.1 0.1 0.2 4 12 
I,9 20 0.9 30 I.0 >I20 2 
114 >I20 25 >I20 IX 5120 I50 
>I20 46 28 41 I8 9120 >750 
>I20 >I20 >I20 >I20 >I20 2120 80 
r120 >I20 20 s120 49 .I20 111 
IX 15 5 14 4 UO 6 
29 82 42 %I70 92 >I50 nt 
IIIIIl----- 
Vitreneetin baminin Pl (GRGDS, cRGDEV) or distinctly lower inhibitory ca- 
pacity (Table I). 
Inhibiter IJMI 
Fig. 1. Inhibition of A375 cell adhesion to vitronectin and laminin 
fragment Pl substrates by linear GRGDS peptide (e) or the cyclic 
pentapeptide RGDFV possessing either D-Phe (A) or D-Val (a). Cell 
adhesion in the absence OF inhibitors was set at 100%. 
hesion to collagen IV and laminin E8 substrates was 
insensitive to inhibition by both peptides, with I&, va- 
lues distinctly above 500,~M. This is in accordance with 
previous data [21,22,26] showing that these adhesions 
are mediated by integrins czl/?l, a2pl or a6@1 which 
belong to the RGD-insensitive cell receptors [6]. It also 
indicates that the high inhibiting activity of cRGDW 
peptide for vitronectin and laminin Pl adhesion is not 
due to cytotoxic or other effects unrelated to integrin 
recognition. 
Purified platelet integrin czIIb/U was used to analyze 
RGD-dependent binding to fibrinogen. In the biotinyla- 
ted form it bound strongly to immobilized fibrinogen 
but not to vitronectin and laminin Pl. The binding to 
fibrinogen could be most efficiently inhibited by soluble 
fibrinogen with IC& = 0.17 PM. About IO-fold higher 
concentrations were required for the same inhibition 
with the most active cyclic peptide cRGDFV (Fig, 2). 
Other peptides tested were of either moderately 
r 
Inhibitor (NH) 
Pig. 2. Inhibition of binding of biotinylatcd intcgrin aIlb/?3 to im- 
mobilized fibrinogen. Inhibitors used were fibrinogen (C I)~ lincar 
GRGDS (A) and the cyclic pcptidcs cRGDF,J! (o), cRGDEV (b) a~! 
cRADFV (n). Non-inhibited binding is set at 100%. Undcrliacd 
rcsiducs correspond to D4somers. 
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The conformations of the 2 most active inhibitors 
cRGDFV and cRGDF% were established by 2D NMR 
spectroscopy and IV 3 simulations performed in a 
DMSQ solvent box [I7,18,27]. Both peptides were sim- 
ilar in adopting an all-trans conformation with a PII’ 
turn and y turn structure in which the D-amino acid 
occupies the i+l position of the PII’ turn (Fig. 3). The 
major difference is the position of the RGD sequence 
relative to the BII’ turn and y turn, and the formation 
of a different amide-carbonyl hydrogen bond stabil- 
izing the PII’ turn. These bonds are ‘between Arg-amide 
and Asp-carbonyl in the D-Phe peptide and between 
Gly-amide and Phe-carbonyl in the D-Val peptide. In- 
terestingly, the distance between Phe-carbonyl and Gl 
K 
- 
amide in the D-Pile peptide is relatively short (3.1 ) 
strongly suggesting that the peptide may change to the 
conformation of the D-Val variant. Model building 
studies in fact support such a transition from one to 
another /WY conformation. One can simulate by MD 
with dihedral restraining a conformational transition of 
cRGDEV via an intermediate BITi turn arrangement, 
shifted by one residue compared to the initial conforma- 
tion. A conversion of the yi into a y turn results in a 
backbone conformation identical to that determined for 
cRGDFy. A comparable turn rearrangement is not so 
easy to perform for cRGDFV, because it lacks the 
structural requirements for the interconversion into the 
conformation of cRGDIFV. For example, the large dis- 
tance (7 A) between Asp-carbonyl and Arg-amide in 
cRGDFY prevents a simi!ar conformational change. 
Hence, the proposed transition between 2 conforma- 
tions could easily explain why the D-Phe peptide effi- 
ciently competes against cell adhesion to both, vitronec- 
tin and fragment Pl, while the less flexible D-Val pep- 
tide may be a more selective inhibitor for laminin Pl 
adhesion. 
The strong reduction in inhibiting activity after Gly 
to Ala substitution in the cyclic pentapeptide is most 
likely explained by steric hindrance of binding by a 
single methyl group such as found before for linear 
RAD sequences [2,7]. This is particularly obvious for 
cRADEV which should have a conformation almost 
identical to that of active cRGDFV while loss of activity 
in cRADFV may also be due to a shift in the positions 
of the PII’ and y turns. Such shifts could also explain 
the low activity of the peptides c.RGDFV and cRCDFV 
which by analogy to the conformations shown in Fig. 
3 would place the essential RGD sequence into a differ- 
:nt context within the /?II’y turns. The low activity of 
the cyclic D-Arg variant was of particular interest, since 
replacement of L-Arg by D-Arg in the linear GRGDSP 
Feptide did not cause any substantial change in inhibi- 
.tng aclivily fol vitroncctin and fibroncctin adhesion 
substrates [a]. 
In order to further charactcrizc the conformatiotlal 
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Fig. 3. Stereoplots ofthe conformations of the most active peptides cRGDEV (top) and cRGDFV (bottom) based on 2D NMR and MD simulation. 
Large ciecles how carbon (open), oxygen (filled) and nitrogen (stippled) atoms. Polar hydrogen atoms are indicated by small circles. The/III’ turn 
is shown at the top of each pcptide. Essential hydrogen bonds stabilizing the PII’ turn and the y turn are indicated by dashed lines. Arrows in the 
upper peptide indicate amide and cdrbonyl groups involved in a possible transition to the conformation of the lower peptide. Both conformations 
are consistent with experimental NOE data and the temperature coefficients of the NH resonances of protons involved in hydrogen bonds being 
in the range of ANAT = -0.75 to 3.78 ppb/K. 
constraints which impose high biological activity upon 
the cyclic RGDEV peptide, several cyclic hexapeptides 
cRGDlFVA containing a single D-amino acid were syn- 
thesized. Peptide cRGDEVA, which most closely 
resembles one of the active cyclic pentapeptides, was of 
3-5-fold lower inhibiting activity for laminin PI adhe- 
sion when compared to linear GRGDS. Conformatio- 
nal analysis of this hexapeptide showed, as expected, an 
all-trarts conformation with D-Phe in i+- 1 position of a 
pII’ turn, but a PIE turn with Arg in i-l-1 and Gly in i+2 
positions instead of a y turn, The distance between 
p-carbons of Arg and Asp which was 7.8 A in the hexa- 
peptide and only 6.6 A in the pentapeptide was a further 
substantial difference. We assume that these conforma- 
tional differences are mainly responsible for the large 
differences in biological activity between both cyclic 
peptides, We have previously also utilized a synthetic 
peptide for inhibition [13] comprising the authentic la- 
minin A chain sequence [28] CQAGT- 
FALRGDNPQGCSP-amide. This peptide, when used 
in either linear or cyclic disulfide-bonded form, was no 
better an inhibitor than GRGDS for Pl substrates. This 
emphasizes that the steric restrictions imposed in small 
rings are crucial for the specific conformation required 
for efficient binding to RGD-sensitive integrins. In ad- 
dition, the precise position of RGD within BII’ and y 
turns as well as the chirality of the spacer residues (Phe, 
Val) may contribute to the acliviiy find sa!ectivity of 
binding. 
inhibits cell adhesion to vitronectin about IO-fold better 
than the linear variant [8]. NMR analysis of this peptide 
[I l] demonstrated 2 consecutive @I turns and a y turn. 
This particular conformation may explain the lower 
relative inhibiting activity observed for this structure 
when compared to cRGDEV (Table I). A comparable 
lOO-fold increase’ in inhibiting activity for vitronectin 
adhesion was recently reported for the cyclic hepta- 
peptide cGR.GDSPA when compared with the linear 
form, while smaller cyclic RGD peptides were far less 
active [29]. Here, it remains interesting to analyze to 
what extent the conformation of the cyclic heptapeptide 
comprises that of cRGDEV. 
The high inhibiting activity of cyclic RGDEV and 
RGDFV peptides for certain but not all adhesion reac- 
tions was not predictable. However, the synthetic ap- 
proach adopted was successful and also permitted the 
correlation of activity with distinct conformational fea- 
‘tures. The selectivity of inhibition will be useful in ana- 
lyzing the receptors involved and to study their biologi- 
cal functions. In addition, such cyclic peptides are likely 
to be metabolically more stable than linear sequences, 
which may be an advantage for in vivo studies of deve- 
lopmental processes or tumor metastasis [30]. 
Other studies have shown that the disulfide-bonded 
pcptide GPcnGRGDSPCA (where Pen is penicitlnmine) 
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